Clinical course, complications, and requirement for advanced therapy in patients with ulcerative colitis

Authors

DOI:

https://doi.org/10.22516/25007440.1535

Keywords:

Ulcerative colitis, inflammatory bowel diseases, longitudinal studies, biological therapy

Abstract

Introduction: Ulcerative colitis is a chronic inflammatory bowel disease whose clinical course and therapeutic requirements have been described mainly in North American and European cohorts. In Latin America, information from real-world longitudinal studies remains limited.

Methodology: Researchers conducted a retrospective case series that included adult patients with a confirmed diagnosis of ulcerative colitis treated at a Colombian referral center between January 2020 and April 2025. They collected sociodemographic variables, disease extent, treatments received, intestinal and extraintestinal complications, surgical requirements, and use of advanced therapies. The analysis was descriptive.

Results: The study included 53 patients, with a predominance of women (60.4%). Proctitis was the most frequent presentation (41.7%). A total of 28.3% experienced at least one intestinal complication, and bleeding requiring hospitalization was the most common (18.9%). Extraintestinal manifestations occurred in 15.1%, while 9.4% required surgical management. A total of 30.2% were refractory to conventional therapy and required escalation to advanced therapies, initiated on average 46 months after diagnosis; vedolizumab was the most frequently used agent.

Conclusions: A significant proportion of patients with ulcerative colitis in this Colombian case series developed complications and required advanced therapies, generally at a late stage. These findings provide local real-world evidence and highlight the need to optimize follow-up and timely therapeutic escalation.

Downloads

Download data is not yet available.

Author Biographies

Gustavo Adolfo Reyes Medina, Fundación Santa Fe de Bogotá

 Institutional Gastroenterologist, Fundación Santa Fe, Bogotá, Colombia.

Maria Alejandra Gomez Gutierrez, Fundación Santa Fe de Bogotá

Physician, Research Assistant, Fundación Santa Fe, Bogotá, Colombia.

Adriana Margarita Rey Rubiano, Fundación Santa Fe de Bogotá

Institutional Gastroenterologist, Fundación Santa Fe, Bogotá, Colombia.

Rafael García-Duperly, Fundación Santa Fe de Bogotá

Colorectal Surgeon, Fundación Santa Fe, Bogotá, Colombia.

Jose De la Hoz-Valle, Fundación Santa Fe de Bogotá

Physician, Clinical Epidemiology Specialist, PhD in Biomedical Sciences; Head of the Clinical Studies Division, Fundación Santa Fe, Bogotá, Colombia.

Ivan Camilo Triana Avellaneda , Fundación Santa Fe de Bogotá

Physician, Epidemiologist, Research Assistant, Fundación Santa Fe, Bogotá, Colombia.

Zamira Fernanda Gómez Giraldo, Fundación Santa Fe de Bogotá

Physician, Research Assistant, Fundación Santa Fe, Bogotá, Colombia.

Juan Diego Castro-Córdoba, Fundación Santa Fe de Bogotá

Physician, Research Assistant, Fundación Santa Fe, Bogotá, Colombia.

Miguel Felipe Cárdenas Mesa, Universidad de Los Andes

Medical Student, Universidad de los Andes, Bogotá, Colombia.

Maria Carolina Barrios Dominguez, Fundación Santa Fe de Bogotá

Physician and Surgeon, General Surgery Resident, Fundación Santa Fe, Bogotá, Colombia.

Fernando Sierra Arango, Fundación Santa Fe de Bogotá

Internal Medicine Physician, Gastroenterologist, Master’s Degree in Clinical Epidemiology; Director of the Clinical Studies Division and Head of the Department of Gastroenterology, Fundación Santa Fe, Bogotá, Colombia.

References

Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-1770. https://doi.org/10.1016/S0140-6736(16)32126-2

Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. Dtsch Arztebl Int. 2020;117(33-34):564-574. https://doi.org/10.3238/arztebl.2020.0564

Balderramo D, Quaresma AB, Olivera PA, Savio MC, Villamil MPG, Panaccione R, et al. Challenges in the diagnosis and treatment of inflammatory bowel disease in Latin America. Lancet Gastroenterol Hepatol. 2024;9(3):263-272. https://doi.org/10.1016/S2468-1253(23)00284-4

Juliao-Baños F, Kock J, Arrubla M, Calixto O, Camargo J, Cruz L, et al. Trends in the epidemiology of inflammatory bowel disease in Colombia by demographics and region using a nationally representative claims database and characterization of inflammatory bowel disease phenotype in a case series of Colombian patients. Medicine (Baltimore). 2021;100(7):e24729. https://doi.org/10.1097/MD.0000000000024729

Kotze PG, Underwood FE, Damião AOMC, Ferraz JGP, Saad-Hossne R, Toro M, et al. Progression of Inflammatory Bowel Diseases Throughout Latin America and the Caribbean: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18(2):304-312. https://doi.org/10.1016/j.cgh.2019.06.030

Ciapponi A, Virgilio SA, Berrueta M, Soto NC, Ciganda Á, Rojas Illanes MF, et al. Epidemiology of inflammatory bowel disease in Mexico and Colombia: Analysis of health databases, mathematical modelling and a case-series study. PLoS One. 2020;15(1):e0228256. https://doi.org/10.1371/journal.pone.0228256

Yepes Barreto I, Carmona R, Díaz F, Marín-Jiménez I. Prevalencia y características demográficas de la enfermedad inflamatoria intestinal en Cartagena, Colombia. Rev Colomb Gastroenterol. 2010;25(2):107-111.

Rojas CA, Sánchez-Londoño S, Rojas NE, Sepúlveda M, García J, Jiménez D, et al. Descripción clínico-epidemiológica de pacientes con enfermedad inflamatoria intestinal en una clínica de cuarto nivel en Cali. Rev Colomb Gastroenterol. 2020;35(2):166-173. https://doi.org/10.22516/25007440.409

García-Duperly R, López-Panqueva R, Londoño-Schimmer EE, Rey-Rubiano M, Padrón-Mercado J, Medellín-Abueta A, et al. Características de la enfermedad inflamatoria intestinal con respecto a otros centros nacionales de Colombia. Rev Colomb Gastroenterol. 2022;37(1):48-57. https://doi.org/10.22516/25007440.752

Juliao-Baños F, Puentes F, López R, Saffon MA, Reyes G, Parra V, et al. Characterization of inflammatory bowel disease in Colombia: Results of a national register. Rev Gastroenterol Mex. 2021;86(2):153-162. https://doi.org/10.1016/j.rgmx.2020.05.005.009

Reyes GA, Gil FL, Carvajal GD, Sánchez CB, Aponte DM, Gonzáles CA, et al. Enfermedad inflamatoria intestinal: características de fenotipo y tratamiento en un hospital universitario de Bogotá, Colombia. Rev Colomb Gastroenterol. 2018;33(2):117-126. https://doi.org/10.22516/25007440.196

Selvaratnam S, Gullino S, Shim L, Lee E, Lee A, Paramsothy S, et al. Epidemiology of inflammatory bowel disease in South America: A systematic review. World J Gastroenterol. 2019;25(47):6866-6875. https://doi.org/10.3748/wjg.v25.i47.6866

Figure 1. Disease location at diagnosis (n = 53). Image courtesy of the authors.

Published

2026-09-11

How to Cite

Reyes Medina, G. A., Gomez Gutierrez, M. A., Rey Rubiano, A. M., García-Duperly, R., De la Hoz-Valle, J., Triana Avellaneda , I. C., … Sierra Arango, F. (2026). Clinical course, complications, and requirement for advanced therapy in patients with ulcerative colitis. Revista Colombiana De Gastroenterología, 41(3), 303–308. https://doi.org/10.22516/25007440.1535

Issue

Section

Originals articles

Altmetric

Escanea para compartir
QR Code
Crossref Cited-by logo
Article metrics
Abstract views24
Galley views11
PDF Views11
HTML views0
Other views0

Some similar items: